Skip to Main Content

Paper Details

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
JAMA Oncol
11
2022
Author NameAffiliation
Eve A KerrVeterans Affairs Center for Clinical Management Research
Eve A KerrUniversity of Michigan ann arbor
  • 1 - 2

Datasets

Release 1.2